A Pilot Trial of the Combination of Transgenic NY-ESO-1–reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab





In this study we examined the safety and feasibility and antitumor efficacy of Transgenic adoptive cell therapy (ACT) with Dendritic Cell (DC) vaccination, with and without CTLA-4 blockade with ipilimumab. Results reveal the treatment is feasible and results in transient antitumor activity, with no apparent clinical benefit of the addition of ipilimumab.

Patients characteristics

The malignancies treated included synovial sarcoma (n=5), metastatic melanoma (n=2), and one each with osteosarcoma, liposarcoma, and malignant peripheral nerve sheath tumor. Patients had stage IIIc or stage IV disease and had progressed on standard-of-care chemotherapy/radiotherapy regimens, as well as a variety of experimental therapies.


Patients were then admitted and received lymphodepleting chemotherapy consisting of cyclophosphamide 60 mg/kg/day x2 days intravenously on days -5 and -4, and fludarabine 25 mg/m2/day x4 days intravenously from day -4 to -1.
Patients received their first dose of 1 mg/kg ipilimumab, intradermal administration of NY-ESO1 peptide–pulsed DCs and began low-dose IL2 therapy (500,000 IU/m2 s.c.) the following morning (day +1) twice daily for up to 28 doses (patients ESO-1, ESO-2, ESO-3, ESO-4, INY-1, INY-2) or 14 doses (patients ESO-5, ESO-6, INY-3, and INY-4), as tolerated.
Patients continued to receive two more doses of DC vaccines at 2-week intervals and 1 mg/kg ipilimumab every three weeks for four total doses (if on the INY protocol).Six patients were enrolled in the ESO cohort, and four were enrolled in the INY cohort.


Safety and feasibility
There were no serious toxicities in all 10 patients in both protocols beyond known toxicities that were attributed to the conditioning chemotherapy, systemic IL2 therapy, and ipilimumab therapy, and these serious toxicities were generally reversible.
At the formal restaging PET/CT scans on day +90, 2 of the patients treated per ESO had evidence of a partial response by RECIST1.1. One patient treated per ESO had a partial response (PR) that eventually progressed to a complete response (CR) without additional therapy and has had an ongoing CR for over four years.
Clinical responseIn ESO cohort, 2 patients achieved partial response (both synovial sarcoma) with OS of 43 and 51 months (progressed to complete response). 2 patients had progressed disease (osteosarcoma and synovial sarcoma) with OS of 19 months and 25 months respectively.In INY cohort, all 4 patients had progressed disease with OS of 2, 3, 6 and 29 months.


In conclusion, the manufacture and administration of transgenic NY-ESO-1 TCR T cells with NY- ESO-1 peptide-pulsed DC vaccine with or without ipilimumab is generally safe, feasible, and results in frequent initial antitumor activity. Addition of ipilimumab, while safe and feasible, had no apparent effect on transgenic cell persistence, transgenic cell phenotype, or overall clinical response.

Article Reference link: click here

Scientific article publishing date 1/4/2019

Immucura identifier BSC21_068EN